Home  >  Products  >  TNFRSF13C (tumor necrosis factor receptor superfamily, member 13C ) Blocking Peptide (the C terminal of TNFRSF13C)(100ug)
TNFRSF13C (tumor necrosis factor receptor superfamily, member 13C ) Blocking Peptide (the C terminal of TNFRSF13C)(100ug)

TNFRSF13C (tumor necrosis factor receptor superfamily, member 13C ) Blocking Peptide (the C terminal of TNFRSF13C)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-TNFRSF13C Antibody (ARP63621_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63621
Size: 100ug
Weight: 20kDa
Gene: 115650
Format: Lyophilized powder
Target: B cell-activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of Baff in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival.
Alternative names: BAFF-R; BAFFR; CD268; MGC138235
See Full Product Listings >